KEYNOTE-183 and OPTIMISMM: creating new standards of care for R/R MM
Description: Maria-Victoria Mateos, MD, PhD, from the University Hospital of Salamanca, Salamanca, Spain, discusses clinical trials that are currently investigating the effects of single-dose drugs and combination therapy for the management of relapsed/refractory multiple myeloma (MM). The OPTIMISMM trial (NCT01734928) is a Phase III study evaluating the efficacy and safety of pomalidomide, bortezomib and low-dose dexamethasone vs. bortezomib and low-dose dexamethasone; and the KEYNOTE-183 (NCT02576977) trial is investigating the effects of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in patients that have already undergone at least two lines of prior treatment. This interview was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.
Shared By : VJHemOnc
Posted on : 07/16/18
Added : 1 year ago